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Abstract
Background:  The article is devoted to a try to reconsider a main 
paradigm of contemporary oncology, the hypothesis of cancer me-
tastasis.
Methods:  The investigation was based on the reassessment of well 
known data about cancer epidemiology and clinical manifestations 
from the viewpoint of recent all-pathological, immunological, ge-
netic and evolutionary discoveries.
Results:  The potentially cancerous cell clones settled a human 
body as a result of crossbreeding between persons with partially 
different genomes. The clones appeared in the body before post-
natal ontogenesis and for many decades exist in it as multiple but 
smallest stochastically distributed cell populations. But at relevant 
time of individual life (mainly after 40 years of age), according to 
own specific programs of the clone  ontogenesis, it begin to multiple 
uncontrolled thus initiating the cancerous growth being unregulated 
by usual cyto-ecological agents owned by affected body. Its cells 
come into sight as constitutionally immune to normal regulators of 
cell reproduction and tissue growth.
Conclusions:  The new notion provides a framework for under-
standing the epidemic nature of cancer and its rising incidence both 
in the developed world and in developing countries. It forces also 
to reassess the means and methods of cancer healing. What is more, 
it accents the possibility of genetic methods for the prevention of 
epidemic spread of the disease.
Keywords:  Cancer epidemiology; Cancer pathogenesis; Genet-
ics of cancer origin; Genetic immunity; Molecular physiological 
regulation
Introduction
Cancer is the second most common cause of death in 
many developed countries. In the USA, for instance, cancer 
is accounted for 1 of every 4 deaths. It is exceeded today 
only by cardiovascular diseases. What is more, the cancer 
incidence  continues  to  arise.  Despite  considerable  epide-
miological, immunological, genetic, surgical and pharmaco-
logical efforts, cancer continues to increase its toll in human 
death. Beside, the efficacy of means recommended for can-
cer prevention and treatment is very low. 
The knowledge of origin and initial causes of the dis-
ease is far away of satisfactory clearness but contains some 
questionable assertions including both the compulsory ex-
istence of maternal (primary) tumor and inevitable spread 
(metastasis) of cancer cells from maternal tumor to form new 
(daughter’s) tumors in distant locations in the body. Distant-
site metastases are considered the leading cause of cancer-
associated mortality. 
It is thought the cancer cells spread mainly through the 
bloodstream or the lymph system. But in reality only the end 
point of the process--macroscopic metastases is observed. 
The details of the metastatic process remain hypothesized 
and mysterious [1]. The present article is devoted to a try 
to initiate a revision of the two questionable assertions of 
contemporary oncology basing on well known data about the 
cancer manifestations and course [2] in comparison with the 
data  of  recent  all-pathological,  epidemiological,  immuno-
logical and genetic discoveries. 
The preliminary hypothesis was that potentially cancer-
ous cell clones appear in a body as a result of interbreed-
ing between persons with partially different genomes. The 
clones arise in the body during yearly stage of ontogenesis 
and for many decades exist in it as multiple but smallest sto-
chastically distributed cell populations in full concordance 
with general rules of the regulation of cell reproduction and 
tissues’ growth. But at relevant time of individual age (main-
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ly after 40 years of life), according probably to own specific 
program of ontogenesis, the cells of relevant clone begin its 
malignant  development  being  constitutionally  immune  to 
normal cyto-ecological regulators. 
Materials and Methods
The investigation was based on the reassessment of well 
known data about cancer epidemiology and clinical mani-
festations from the viewpoint of recent all-pathological, im-
munological, genetic and evolutionary discoveries. The first 
step in this new contribution to cancer descent and epidemic 
spread has been initially supported by the Science Advisory 
Board publication on www.scienceboard.net [3].
 
Results
The investigation included, first of all, the recently dis-
covered  all-pathological  prerequisites  (a),  for  subsequent 
reassessment of the unique and ordinary features of cancer 
disease (b), and the data of recent discoveries on genetic 
immunity  of  cells  against  molecular  cyto-physiological 
regulators(c). The preliminary results allowed proposing a 
model of cancer molecular pathogenesis (d) and explaining 
the specificity of genetic predilection to cancer (e).
(a) All-pathological prerequisites
Beside with very specific and extraordinary various man-
ifestations any disease displays also a set of universal signs 
that are characteristic of any other disease too. Each of these 
universal features illustrates all-pathological phenomenon of 
heterozygous mosaicism created by genetic admixture. The 
mosaicism is the condition in which the phenomenon of het-
erozygosity reveals genetically determined variations in the 
locations, sizes and other pathological manifestations of any 
disease on the level of species, populations, organs, tissues, 
cells and molecular make-up of individual bodies [4].
The mosaic composition of living beings arises as a re-
sult of heterozygous self-reproduction. It reveals itself espe-
cially intensively in any form of both infectious and nonin-
fectious pathology determining individual differences in the 
manifestations, course and severity of diseases. This kind of 
biodiversity arises as a result of sexual self-reproduction re-
sulted in hybridization between two genetically different or-
ganisms: one of them is constitutionally immune to relevant 
ecological or physiological agent whereas its mating partner 
is constitutionally sensitive to it. 
The hybridization forms inevitably either this or that 
grade of heterozygosity, which is resulted in the coexistence 
in the body at least of two active allelomorphic genes and of 
two allelic cell clones. Both of these alleles function dom-
inantly. As a result, the cell populations of a descendant’s 
body are formed under control of two codominant allelomor-
phic genes. The heterozygous individual shows both alleles 
expressed equally but in separated sizes and locations around 
the body [4].
(b) The uniqueness and ordinariness of cancer
Any disease is characterized by a set of universal all-
pathological signs, features. This set includes at least a doz-
en of intrinsic features: a) different incidence of the disease 
among the races and ethnic groups, b) increased prevalence 
of diseases in developed and civilizing  countries, c) ge-
netic predilection to the disease, d) age differences in the 
incidence of disease, e) stochastic distribution of individual 
cases amongst a population, f) individual variations in con-
stitutional (genetic) predilection to the disease, g) the mosa-
icism of affections, i.e. intra-individual diversity both in the 
predilection of different parts of a tissue and in the quantity 
and sizes of affections, h) stochastic distribution of affec-
tions amongst a body, and i) molecular bases of genomic and 
cellular pathogenesis k) the identity of involved cells in any 
locations of specific affections around the body [4]. Each of 
these well known universal signs is belong to any form of 
cancer. Beside, any of them contains either this or that con-
tradictions to the revised paradigm.
In contrast, unlike to other kinds of diseases the appear-
ance of malignancy is very uniquely, i.e. cancer come in sight 
when the dividing, growth and differentiation of some cells 
in some parts of a body’ tissue are uncontrolled and crazed. It 
occurs when some cells of a tissue are physiologically abnor-
mal and divide without control or order. The disturbance is 
determined by constitutional (genetic) immunity of involved 
cells  against  relevant  molecular  physiological  regulators. 
The cells resistant to hormonal influences have no visible 
distinctions  from  the  susceptible  ones.  In  contrast,  under 
conventional light microscope cancer cells look like abnor-
mal versions of cells which compose the tissue of its origin. 
Light microscopy cannot perform an easy task to identify 
the site of a malignancy origin [5]. Thus the list of cancer 
uniqueness is far shorter than those one of its ordinariness.
(c)  Genetic  immunity  against  molecular  physiological 
regulators
Human body is provided with a physiological system 
that maintains its structures and functions within their ge-
netically  predetermined  locations,  shapes,  sizes  and  mo-
lecular performance. The system acts through the molecular 
mediation i.e. by means of hormones and other molecular 
physiological agents. For instance, a dysfunction can be con-
ditioned by deficiency of relevant hormone production. The 
same result can be achieved by mutant modifications of both 
the hormone and its receptor, which forms an incongruence 
between the co-actors, i.e. constitutional immunity against 
hormone influence [6-8]. 
The  blocking  effect  of  mutant  modification  of  either 
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hormones  or  their  receptors  leads  to  many  pathological 
processes including obesity [9].  The immunity of cells to 
insulin is a major determinant of the decline of glucose tol-
erance.  Similarly,  non-insulin-dependent  diabetes  mellitus 
is characterized by pathological hyperglycemia in the pres-
ence of higher-than normal levels of plasma-insulin. Like-
wise, a pathogenic decrease in cell sensitivity to vitamin D3 
determines the familiar forms of rachitic, and the immunity 
of cells to androgens causes the phenomenon of testicular 
feminization. Analogous resistance of cells to corticosteroids 
determines the pathogenesis of Cushing’s disease [9]. The 
grade of the cells immunity to thyroid hormone determines 
the range of relevant disturbances. This resistance is an in-
herited inability to respond appropriately to the T3 hormone 
linked to mutations in the thyroid hormone receptor (TR)-
beta [10]. 
The principles of cell immunity to physiological agents 
are analogous to those ones in constitutional (genetic) im-
munity to infections [4]. In a case of cancer the work of this 
precise and powerful regulatory system becomes also dis-
turbed specifically. The mutual exposure, analysis and evo-
lutionary comprehension of a set of relevant immunological 
data allowed us to put forward a new idea about molecular 
pathogenesis of cancer.
(d) The proposed molecular pathogenesis of cancer
Humans are extraordinarily diverse in their manifesta-
tions of cancer. Affected people have many individual differ-
ences in manifestations of their cancer as well as in the grade 
of its expression. The shape, location, size and rate of cancer 
progression may be different in different individuals or in 
different organs as well. With the exception of impossible 
total affection on almost all the body that is only observed at 
leukemia, multiple myeloma, and lymphoma, several areas 
of restricted, focal, cancer locations exist in most other kinds 
of cancer. Cancer is presented by focal affections of indi-
vidually different grades and locations [2]. The focalization 
of affections is the principal feature of any disease including 
cancer. 
One can suppose that within any body affected by can-
cer there are initially two co-existing clones of homogenous 
cells with opposite predisposition to the development of the 
disease. The potentially cancerous clone exists in a form of 
distantly separated populations and their initial sizes are dif-
ferent but very small. They are dispersed around the body 
either stochastically or in a manner is not yet understood. 
One should suppose that their dispersion around the body 
has been performed before postnatal ontogeny [11]. Accord-
ingly, the clone is not eliminated by mechanisms of adap-
tive immunity performed by lymphatic system. Initial sub-
populations of a potentially cancerous clone are dispersed 
around the body like congenital small dark spots on human 
skin known as moles, the melanocytic nevuses, that exist in 
a form of benign neoplasm but may be at a higher risk for 
melanoma [12]. 
Different locations of potentially cancerous clone begin 
to be visually detectable in different times after initiation 
of their malignant growth that allow for the supposition of 
differences in their initially smallest sizes. The differences 
in such cancer cell masses and their dislocation around the 
body predestine individual diversity in the course and sever-
ity of cancer when the disease will begin its development. 
Most cells of a cancer clone are mainly located in the 
organ or tissue of their belongingness. Other subpopulations 
of the same clone are located distantly. Some patients may 
have a cancer whose site of origin is hidden and never identi-
fied [5]. Various organs can serve the places for distant parts 
of a cancer to occur (the lungs, liver, brain, bones et al). The 
populations of malignant cells that formed leukemia, mul-
tiple myeloma, and lymphoma are usually not localized but 
dispersed around the affected body like the normal cells of 
the same tissue and relevant cancer cells may be found in the 
blood, several lymph nodes, or other parts of the body such 
as the liver and/or bones [2].
All distant locations of a cancer consist of the cells that 
are like those in the organ or tissue of its origin. This feature 
is paradigmatically considered as a result of metastasis [2]. 
In contrast to the paradigm it can be considered as a result 
of a process that still has yet to be understood, for instance 
either of the process of innate translocation or a transfer of 
a chromosomal segment to a new position, when a part of 
a chromosome is transferred to another chromosome espe-
cially on a non-homologous chromosome. Translocation can 
result in serious congenital disorders like sarcomas, leuke-
mia, dysplasia et al.
For many initial decades of individual life the poten-
tially cancerous cells exist in the body in full concordance 
with  general  rules  of  the  regulation  of  cell  reproduction. 
At a relevant time of individual age (mainly after 40 years 
of life), probably according to specific program of this cell 
population’s ontogenesis, an unknown event induces their 
malignant development. Before or at the time the induction 
began the cells may be constitutionally resistant to normal 
regulators of both cell reproduction and the growth of cell 
populations inside. The existence of its constitutional im-
munity against relevant physiological regulators should be 
considered as the obligate prerequisite to malignity.
(e) The specificity of genetic  predilection to cancer
Although it is now an obvious truism that a person’s 
genetic makeup has a principal influence on the develop-
ment of cancer, the special characteristics of the genome that 
determine the resistance of cancer cells and  focal distribu-
tion of cancer around the body are unknown. In contrast, the 
origin of analogous features of infectious diseases and many 
noninfectious ones as well as the role of constitutional im-
munity in their pathogenesis have been deciphered recently 
by many investigators [4].
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The existence of genetic predilection to cancer is a most 
important source of doubts in the reality of metastasis. The 
predilection is predetermined by a set of genetic factors as-
sociated mainly with genetic admixture and with genesis 
of  aging  [13].  Genetic  admixture  (also  called  xenogamy, 
outbreeding, cross-fertilization, crossbreeding) refers to re-
productive union of genetically dissimilar or unrelated or-
ganisms within the same species that resulted inevitably in 
the offspring’s heterozygosity of various kinds. The states 
of heterozygosity are responsible for the origin, manifesta-
tions, course and severity of most diseases, both infectious 
and non-infectious ones [4]. Increased incidence of most 
diseases depends on the intensity of the population’s genetic 
admixture. For instance, the number of obese people is in-
creased in the territories with ethnically-mixed populations 
[9]. 
The role of xenogamy in the origin, manifestations and 
course of malignant diseases is evidenced by a plethora of 
epidemiological  and  clinical  observations  and  investiga-
tions. African Americans are more likely to die from cancer 
then any other racial or ethnic population. In contrast, His-
panics, Asian Americans and Pacific Islanders have lower 
incidence rates than whites for the most common cancers. 
The frequency of colorectal cancer varies around the world. 
It is common in the Western world and is rare in Asia and 
Africa [2]. The cancerous insertion in the genome of human-
kind could happen on the yearly stages of anthropogenesis 
as a result of genetic admixture. This highly pathogenic in-
sertion has not been eliminated by natural selection probably 
because it begins to function at the end of reproductive age.
Although only one cancerous clone exists usually in an 
affected body, the benigness of a number of such clones is 
documented too. Approximately one third of cancer survi-
vors aged  > 60 years were diagnosed more than once with 
another cancer. Possibly, this is associated with the phenom-
enon of intra-individual diversity in the progression of se-
nescence [13]. In a population of a developed country with 
high survival rates multiple cancers comprise two or more 
primary cancers occurring in an individual that originate in 
a primary site or tissue and are neither an extension, nor a 
recurrence or metastasis [14]. Cancer patients have a 20% 
higher risk of new primary cancer compared with the general 
population. As the number of cancer survivors and of older 
people increases, occurrence of multiple primary cancers is 
also likely to increase [14-18]. Such observations induce the 
idea about possible existence in a body of few potentially 
cancerous clones.
Discussion
  
The mutual exposure, analysis and evolutionary com-
prehension  of  epidemiological,  clinical,  immunological, 
genetic and experimental data concerning principal charac-
teristics of cancer showed that many of them are also com-
mon to those of other kinds of diseases. Cancer is determined 
by a constitutional immune incongruence between relevant 
molecular cytoecological agents and their molecular targets. 
These features of individual molecular constitution exist in 
a population as a result of genetic admixture between people 
evolved in ecologically-distinct environments and have got 
differences in their molecular constitution on the level of 
cytoecological regulators of cell growth, development and 
differentiation. 
Individual and intra-individual diversity in the cancer 
course, including the manifestations and severity of specific 
affections, their sizes and focal disposition around the body, 
could be created by inter-ethnic mating of persons with in-
congruent  regulator-receptor  systems.  Thus,  according  to 
the hypothesis formulated and examined above, the genesis 
of cancer and its spread in human population are associated 
with both evolutionary formation of inter-ethnic differences 
and genetic admixture between genetically different persons. 
In these circumstances, we should remember the com-
mandment of Abraham: “… you will not take a wife…from 
the daughters of the Ca’naan’ites in among whom “… we 
are dwelling? [19]. The refusal of genetic admixture could be 
most effective way to prevent the growth of cancer incidence. 
What are the tests for the existence of cancerous genetic ad-
mixture that should be elaborated today and used tomorrow? 
The new notion on cancer origin, immuno-pathogenesis and 
epidemic spread provides a framework for understanding the 
epidemic nature of cancer and its rising incidence both in the 
developed world and in developing countries. It forces also 
to reassess the means and methods of cancer healing. What 
is more, it accents the possibility of genetic methods for the 
prevention of epidemic spread of the disease.
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